Email Updates

Search form

You are here

HVTN 502 (STEP study)

Status
Stopped Early
Phase
IIb
Objective

To continue evaluating the safety and begin evaluating the efficacy of an investigational HIV vaccine. 

Prevention Option(s)
HIV Vaccine
Study Design
Controlled
Randomized
Double-blind
Arms and Assigned Interventions
Description
MRKAd5 HIV-1 gag/pol/nef trivalent vaccine
Mode of Delivery
Intramuscular
Products
Ad5
ARMs
Experimental
ARMs
Placebo Comparator
Trial Sponsors
NIAID, SAAVI
Product Developers
Merck
December 2004
September 2007
18
Years
45
Years
Population
Women
Men
Sites

Site(s) - United States

United States of America

Site(s) - Peru

Peru

Site(s) - Brazil

Brazil

STEP CRS

Santo Domingo
Dominican Republic

STEP CRS

Port-au-Prince
Haiti

STEP CRS

Kingston
Jamaica

STEP CRS

San Juan
Puerto Rico

STEP CRS

Sydney
Australia

Site(s) - Australia

Australia